E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Liver cirrhosis and portal vein thrombosis |
Cirrosis hepática y trombosis de la vena porta |
|
E.1.1.1 | Medical condition in easily understood language |
Liver disease in advanced stage, with the possibility of developing portal vein thrombosis (occlusion of the vein that carries blood to the liver) |
Enfermedad hepática en fase avanzada, con posibilidad de desarrollar trombosis en la vena porta (oclusión de la vena que lleva la sangre al hígado) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Determine whether anticoagulation with rivaroxaban improved transplant free survival and hospital admissions for hepatic decompensation or significant bleeding complications without progression of thrombosis |
Determinar si la anticoagulación con rivaroxaban mejora la supervivencia libre de trasplante y de presentar ingresos hospitalarios por descompensación hepática o complicaciones hemorrágicas significativas y sin progresión de la trombosis |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the efficacy for recanalization of portal vein thrombosis. - To evaluate the efficacy to prevent decompensated cirrhosis complications of portal hypertension (ascites, spontaneous bacterial peritonitis, ruptured variceal haemorrhage or hepatorenal syndrome). - Evaluate the effectiveness in reducing the number of hospital admissions due to decompensated cirrhosis. - Evaluate the safety of withdrawal rate with rivaroxaban anticoagulant therapy due to adverse effects. - Assess the effect on hepatocellular function (Child-Pugh y MELD). - Assess the effect on inflammatory parameters and bacterial translocation. |
- Evaluar la eficacia para recanalizar la trombosis portal. - Evaluar la eficacia para prevenir la descompensación de la cirrosis por complicaciones de la hipertensión portal (ascitis, peritonitis bacteriana espontánea, hemorragia por rotura de varices o síndrome hepatorrenal). - Evaluar la eficacia para reducir el número de ingresos hospitalarios por descompensación de la cirrosis. - Evaluar la seguridad de tasa de abandono de la terapia anticoagulante con rivaroxaban por efectos adversos. - Evaluar el efecto sobre la función hepatocelular (Child-Pugh y MELD). - Evaluar el efecto sobre los parámetros inflamatorios y de traslocación bacteriana. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Age 18-75 years. - Hepatic cirrhosis. - Thrombosis splenoportal axis: 1) >25% on any of the three main vessels (the main trunk of the portal vein, superior mesenteric vein, splenic vein) 2) Thrombosis affects > 50% of at least one of the intrahepatic branches. - Nonterminal Hepatic failure: B7-C12 state in Child-Pugh classification. |
- Edad 18-75 años. - Cirrosis hepatica. - Trombosis del eje esplenoportal: 1) cualquiera de los tres vasos mayores (tronco principal de la vena portal, vena mesentérica superior, vena esplénica) aislado >25%, 2) afectación >50% de al menos una de las ramas intrahepáticas. - Insuficiencia hepática no terminal: estadio B7-C12 de la clasificación de Child-Pugh. |
|
E.4 | Principal exclusion criteria |
Thrombosis: <25% of a single vessel of the splenoportal axis. Patient on the waiting list or evaluation for liver transplantation. Portal cavernoma (chronic and complete occlusion of the portal vein accompanied by a network of small venous vessels). Antiplatelet and/or anticoagulant therapy at the time of inclusion. Platelet count equal or less than 30,000 platelets/mm3. Renal failure (creatinine clearance <15 ml/min). Severe or terminal liver failure (≥ 13 points Child-Pugh classification). Active intra or extrahepatic neoplasia. Clinically significant active bleeding. Alcohol consumption ≥ 60 g/day in men and ≥ 40 g/day in women. Pregnancy- lactation |
Trombosis aislada <25% de un sólo vaso del eje esplenoportal. Paciente en lista de espera o en evaluación para trasplante hepático. Cavernoma portal (oclusión crónica y completa de la vena porta acompañada de una red de pequeños vasos venosos en su trayecto). Tratamiento con anticoagulantes y/o antiagregantes en el momento de la inclusión. Recuento plaquetario igual o inferior a 30.000 plaquetas/mm3. Insuficiencia renal (aclaramiento < 15 ml/min). Insuficiencia hepática grave o terminal (≥ 13 puntos de la clasificación de Child-Pugh). Neoplasia intra o extrahepática activa. Hemorragia activa clínicamente significativa. Consumo de alcohol ≥ 60 gramos/día en varones y ≥ 40 gramos/día en mujeres. Embarazo- lactancia. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Transplant free survival, without hospital admissions due to liver decompensation or significant bleeding complications, without thrombosis progression |
Supervivencia libre de trasplante, sin ingresos hospitalarios por descompensación hepática o por complicaciones hemorrágicas significativas, sin progresión de la trombosis |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Each visit |
En cada visita. |
|
E.5.2 | Secondary end point(s) |
- Significant bleeding from any cause. - Cirrhosis complications requiring hospital admission (ascites, hemorrhage, Hepatic encephalopathy grade II or higher). - Progression of portal thrombosis. |
- Hemorragia significativa por cualquier causa. - Complicaciones de la cirrosis que requieran ingreso hospitalario (ascitis, episodio de hemorragia por cualquier causa, encefalopatía hepática grado II o superior). - Progresión de la trombosis portal. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Each visit |
En cada visita |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
El estudio finalizará cuando el último paciente realice la última visita |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |